Three patients received RP2 monotherapy injections into the liver: durable PR, durable PR, pseudoprogression that's now SD (in genomically stable CRC). 3/3 disease benefit. No safety problems. T-VEC study: https://t.co/d96RVILymi RP2 poster: https://t.co/
Clinical trial using viruses to kill cancer results in uninjected cancer cells regressing due to immune response https://t.co/lqe4Lwr7kn
RT @bradpalm1: Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma https://t.co/FuSOjduSar $PVCT
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma https://t.co/FuSOjduSar $PVCT